How to Review After Overseas IVF Failure: Key Steps and Test Analysis

Opening: Causes of failure cases (random mechanism 7)

Reproductive Doctor's Observation · A 39-year-old woman, AMH 1.1 ng/mL, underwent her second IVF at an overseas center. A 4AA blastocyst was transferred but did not implant. Her first transfer also failed to implant. The patient reported, "My endometrial thickness has always been good, and my hormone levels are normal. I don't know why it failed." A systematic review revealed: overlooked chronic endometritis (CD138+), and a sperm DNA fragmentation rate as high as 32%. These two issues were not covered in routine tests.

Overseas IVF Failure Review: Three Core Directions

After overseas IVF failure, a review is not simply about "restoring the body and trying again." It requires a standardized path to identify the cause of failure. According to clinical statistics, after one failed transfer, systematic testing can identify the cause in about 55% to 70% of cases; after two or more failures, the rate of identifying the cause can increase to over 80%. The review focuses on three core directions: Embryo Potential, Uterine Receptivity, and Maternal Internal Environment.

1. Embryo Potential Assessment

Whether an embryo can successfully implant and continue developing depends first on the normalcy of its chromosome number and structure, and sufficient mitochondrial function. The following tests have the highest priority during the review:

• PGT-A (Preimplantation Genetic Testing for Aneuploidy): Screens remaining embryos or embryos from a new egg retrieval cycle to rule out implantation failure or early miscarriage caused by abnormal chromosome numbers.
• Time-lapse Embryo Development Review: Evaluates the rhythm of embryo cleavage, fragmentation rate, quality of inner cell mass and trophectoderm, and identifies signs of developmental arrest.
• Sperm DNA Fragmentation Index (DFI): Male factors are easily overlooked. A DFI > 30% significantly impairs the embryo's ability to continue developing. Even if a blastocyst forms, the subsequent miscarriage rate increases.
• Mitochondrial DNA Content Test (mtDNA): Available in some laboratories, used to assess the embryo's energy metabolism potential, especially for advanced maternal age or cases with consistently poor embryo quality.

2. Uterine Receptivity Assessment

Whether the uterine environment is ready to accept the embryo is another decisive factor for implantation. Routine ultrasound to check endometrial thickness is insufficient; the following in-depth tests are needed:

• Hysteroscopy: Directly visualizes the uterine cavity to rule out structural abnormalities like polyps, adhesions, fibroids, or septum. After overseas IVF failure, hysteroscopy should be a basic test.
• Chronic Endometritis (CE) Diagnosis: Endometrial biopsy during hysteroscopy with CD138 immunohistochemical staining to determine the presence of plasma cell infiltration. CE occurs in about 30% to 40% of infertile women and can be as high as 60% in those with recurrent implantation failure (RIF).
• ERA (Endometrial Receptivity Array): Analyzes endometrial gene expression to determine if the optimal implantation window is displaced. About 20% to 30% of RIF patients have a displaced window, and ERA can guide personalized transfer timing.
• Endometrial Microbiome Test (EMMA/ALICE): Analyzes the composition of the uterine cavity microbiota to determine if there is an overgrowth of pathogenic bacteria or insufficient Lactobacillus ratio.

3. Maternal Internal Environment Investigation

The endocrine, immune, and coagulation systems form the "soil" environment for embryo implantation and development. The following are key tests to cover during the review:

• Complete Thyroid Function: TSH, FT3, FT4, TPO antibodies, Tg antibodies. TSH > 2.5 mIU/L may negatively impact implantation. Positive antibodies suggest autoimmune thyroiditis.
• Blood Glucose and Insulin Resistance: Fasting blood glucose, fasting insulin, OGTT (Oral Glucose Tolerance Test). Insulin resistance can interfere with endometrial decidualization, reducing receptivity.
• Antiphospholipid Antibodies (APA): Includes lupus anticoagulant, anti-β2-GP1 antibodies, and anticardiolipin antibodies. Antiphospholipid syndrome is a clear cause of recurrent implantation failure and early miscarriage.
• Natural Killer Cells (NK Cells): Activity and percentage of peripheral blood NK cells, and the number of endometrial CD56+ NK cells. Overactivation of NK cells may attack the embryo's trophoblast.
• Blocking Antibodies (APLA): Lack of blocking antibodies prevents the maternal immune system from recognizing and protecting the embryo.
• Thrombophilia (PTS): Includes Protein C, Protein S, Antithrombin III, Factor V Leiden mutation, Prothrombin G20210A mutation, etc. A tendency for thrombosis can impair placental microcirculation.
• Vitamin D Level: Vitamin D deficiency is associated with implantation failure and pregnancy complications. It is recommended to maintain levels above 30 ng/mL.

Table: Investigation strategies for different numbers of failures

Stratified by Number of Failures: Testing Strategy and Priorities

Different numbers of failures correspond to different depths of investigation. The following is a commonly used clinical stratification plan:

Note: The above stratification applies to individuals under 35. For those aged ≥35 or with AMH < 1.2 ng/mL, it is recommended to proceed to advanced testing after the first failure.

Differences in Review Focus by Age Group

Age is the strongest independent factor affecting IVF outcomes, and the review focus needs to vary by age:

• Under 35 years: The rate of embryonic chromosomal abnormalities is relatively low (about 30% to 40%). The review should prioritize investigating the uterine environment and immune/coagulation factors. In this age group, if recurrent failure occurs, chronic endometritis and immune issues are more likely.
• 35 to 39 years: The embryonic aneuploidy rate rises to 40% to 55%. Chromosomal screening (PGT-A) and embryo morphological assessment should be the core of the review. At the same time, uterine and endocrine factors should not be ignored.
• 40 years and older: The embryonic aneuploidy rate can reach 70% to 85%. Issues with mitochondrial function, embryo metabolism, and chromosomal segment abnormalities are more prominent. The review focus is on embryo-derived problems, while also assessing ovarian reserve (AMH, antral follicle count) and optimizing the ovarian stimulation protocol.

Easiest to overlook details

Three Easiest Details to Overlook

Detail 1: "False Negative" for Chronic Endometritis

The endometrium may appear normal under hysteroscopy, but a biopsy with CD138 staining can still be positive. Some centers only perform HE staining without CD138 immunohistochemistry, missing about 40% of chronic endometritis cases. When reviewing after overseas IVF failure, ensure the pathology report includes CD138 staining.

Detail 2: "Time Window" for Semen Analysis

Sperm DNA fragmentation index can fluctuate over time; a normal result once does not mean it is always normal. When rechecking DFI after overseas IVF failure, request a sample after 2-3 days of abstinence, and also assess oxidative stress markers (e.g., seminal plasma reactive oxygen species ROS). If DFI > 25%, at least 3 months of antioxidant therapy is needed before the next cycle.

Detail 3: Individual Differences in Luteal Phase Support

Different overseas centers use varying luteal phase support protocols, including gels, suppositories, injections, and oral forms. Some patients have low absorption rates for specific forms (especially vaginal gel), leading to insufficient progesterone levels. During the review, it is recommended to test mid-luteal phase progesterone levels (day 4-5 after transfer) to confirm they reach an effective concentration (> 10 ng/mL).

Easiest pitfalls

Four Easiest Misconceptions to Fall Into

1. "Sufficient endometrial thickness is enough": Thickness is just one dimension of receptivity. Endometrial pattern, blood flow, gene expression, and microbiota composition are equally critical. It is very common in clinical practice to have adequate thickness but repeated failure.
2. "This failure was bad luck; just switch to another hospital next time": Changing hospitals or doctors without finding the root cause still carries a high risk of failure. The core of the review is to identify modifiable factors, not to change geographic location.
3. "Doing all tests will find the cause": Even with the most comprehensive tests currently available, about 15% to 20% of patients with recurrent implantation failure will not have a clear cause identified. The goal of the review is to improve the success rate of the next cycle, not to achieve 100% attribution.
4. "Overseas IVF failure means the domestic hospital is not good enough": The reasons for overseas IVF failure are more often related to individual biological factors than to laboratory standards. Unless there is clear evidence of laboratory error (e.g., incubator malfunction, media batch issue), it is not recommended to simply attribute failure to the hospital.

Case scenario analysis

Case Scenario Analysis: Three Typical Review Paths

Scenario 1: Single failed transfer, with frozen embryos

Patient profile: 33 years old, AMH 3.2 ng/mL, 12 eggs retrieved, 5 blastocysts obtained, first transfer failed to implant, 4 blastocysts remaining.

Review recommendation: Hysteroscopy + CD138 staining + Thyroid function + Antiphospholipid antibodies + Vitamin D. If all are normal, consider PGT-A screening on remaining embryos (if not done previously). Also recheck male DFI. In most cases, a single failure can be addressed through basic investigation.

Scenario 2: Two failed transfers, no remaining embryos

Patient profile: 37 years old, AMH 1.6 ng/mL, two egg retrievals yielded 3 blastocysts, all transferred without implantation, no embryos remaining.

Review recommendation: Proceed to comprehensive testing: Hysteroscopy + CD138 + ERA + EMMA/ALICE + Full immune panel (APA, NK, blocking antibodies) + Thrombophilia + Karyotype for both partners + Male DFI. Also evaluate if the stimulation protocol can be optimized (e.g., switch to PPOS protocol or add growth hormone). The goal at this stage is to gather sufficient information for the next egg retrieval.

Scenario 3: Multiple failed transfers, history of biochemical pregnancy

Patient profile: 41 years old, AMH 0.8 ng/mL, 3 transfers all resulted in biochemical pregnancy (hCG positive then declined).

Review recommendation: Prioritize investigating embryonic chromosomal abnormalities (PGT-A), along with hysteroscopy to rule out chronic endometritis and polyps. For immunology, focus on antiphospholipid antibodies and NK cell activity. Due to low AMH, consider a mild stimulation or natural cycle protocol for the next stimulation, adding CoQ10, DHEA, and other mitochondrial support. Biochemical pregnancy indicates the embryo has implantation ability but development is blocked; chromosomal abnormalities and immune factors are the most likely causes.

Frequently asked questions

Frequently Asked Questions After Overseas IVF Failure

Special situation handling

Special Situation: When All Tests Are Normal

About 15% to 20% of patients with recurrent implantation failure, even after all the above tests, still have no clear abnormal indicators. This situation is clinically termed "unexplained recurrent implantation failure" (unexplained RIF). In such cases, consider the following directions:

• Further refinement of embryo factors: Perform whole genome sequencing on existing embryos to detect chromosomal segment abnormalities (CNV) or single gene disorder carrier status.
• More precise assessment of endometrial receptivity: Perform single-cell RNA sequencing on endometrial biopsy to analyze if the proportion of cell subsets is abnormal.
• Maternal-fetal interface immune microenvironment: Evaluate the Th1/Th2 cytokine balance and regulatory T cell (Treg) count in the endometrium.
• Laboratory protocol optimization: Change culture media system, try assisted hatching (AH), use co-culture systems, etc.
• Psychological and lifestyle factors: Chronic stress, sleep disorders, nutritional status, etc., can also affect endometrial receptivity through neuroendocrine pathways.

It is important to clarify: even if all tests are normal, it does not mean there is no hope. Clinical data show that after adjusting the protocol, the live birth rate for the next cycle in patients with unexplained RIF is still 35% to 45%.

Doctor's advice (conclusion)

This content is based on assisted reproductive clinical consensus and reproductive medicine literature and does not constitute personal medical advice. Please develop a specific testing plan with your primary care physician.